What question did this study set out to answer?

To evaluate the efficacy of nivolumab and ipilimumab in patients with melanoma and untreated brain metastases.

August 22, 2018New England Journal of MedicineOpen Access

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

View Full Paper

Ask AI

Bookmark

Authors

HTHussein A. TawbiThe University of Texas MD Anderson Cancer Center PFPeter ForsythMoffitt Cancer Center AAAlain P. AlgaziUniversity of California, San Francisco

Discussion

Member takes

Implication

Randomized trial demonstrates intracranial efficacy of nivolumab combined with ipilimumab in melanoma patients, suggesting a promising treatment approach.

Key Points

To evaluate the efficacy of nivolumab and ipilimumab in patients with melanoma and untreated brain metastases.
Utilized a randomized trial design (CheckMate 204, NCT02320058).
Evaluated effects on patients with melanoma and untreated brain metastases.
Measured both intracranial and extracranial responses.
Nivolumab plus ipilimumab showed clinically meaningful intracranial efficacy.
Intracranial activity correlated with extracranial responses.

Cite This Study

Tawbi et al. (2018) studied this question.

synapsesocial.com/papers/69dcd9bfd111c0385b359697 https://doi.org/10.1056/nejmoa1805453

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates intracranial efficacy of nivolumab combined with ipilimumab in melanoma patients, suggesting a promising treatment approach.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Discussion

Member takes

Implication

Key Points

Cite This Study

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider